Fraser Hall, country president of AstraZeneca Brazil, describes the current trends and dynamics shaping the Brazilian pharmaceutical market and documents the promising partnership opportunities he envisions to significantly increase patient access in both the private and public sectors.
You were appointed country president of AstraZeneca Brazil in September 2016 after having held senior executive positions across several European countries. What are some of the specificities of the Brazilian ecosystem that surprised you most and that you would highlight to our international readers?
"First, our overarching objective is to increase the number of Brazilian patients annually treated with AstraZeneca products from around 3.2 million today to over five million by 2025."
